<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00165828</url>
  </required_header>
  <id_info>
    <org_study_id>ZNS-D-04-001</org_study_id>
    <secondary_id>2005-000260-57</secondary_id>
    <nct_id>NCT00165828</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of an add-on Treatment With Zonisamide in Adults With Focal Epileptic Seizures With or Without Secondary Generalization</brief_title>
  <official_title>Randomized Trial to Assess Efficacy and Safety of an add-on Treatment With Zonisamide in Adults With Focal Epileptic Seizures With or Without Secondary Generalization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <brief_summary>
    <textblock>
      Patients with focal epileptic seizures with or without generalization who are at present
      treated with one or two antiepileptic drugs are eligible for this study, provided that they
      fulfill all inclusion criteria and none of the exclusion criteria. Following a baseline phase
      of 8 weeks duration, the patients are randomised and they receive an initial daily dose of 50
      mg zonisamide during the first week. The daily dose is then increased to 200 mg zonisamide in
      group A or 400 mg zonisamide in group B, respectively. After eight weeks of treatment, the
      daily dose in group A can be increased to 300 mg in case of insufficient efficacy. Control
      assessments are performed at the beginning of the study and at the end of the prospective
      baseline phase, if applicable and after 4, 8, 12, and 16 weeks. At the end of the first,
      second, and third treatment week, and at the end of week six, the patient is additionally
      contacted by telephone. Efficacy and safety parameters are assessed at baseline, during all
      control visits, and at the end of the study.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in number of epileptic seizures between week 13 and 16 after start of treatment compared to the correspondently normalized base-line phase.</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">157</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zonegran</intervention_name>
    <description>Intravenous injection; initial daily dose of 50 mg zonisamide (2x25 mg) in both treatment groups; following a prospective or retrospective baseline phase of 8 weeks the study drug will be administered twice daily during 16 consecutive weeks.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria at screening:

          -  Adult aged between 18 years and 74 years

          -  Focal epileptic seizures with or without secondary generalization

          -  Present treatment with one or two antiepileptic drugs (constant dosage during 8 weeks
             baseline phase prior to initiation of treatment with zonisamide). Stimulation of the
             vagus nerve is permitted and will not be counted as antiepileptic drug.

          -  For women of childbearing potential (postmenopausal for more than 1 year): possible
             pregnancy during the study can be excluded (by hysterectomy, sterilization or
             simultaneous application of two recognized methods of contraception (no oral
             contraceptives only)

          -  For male patients with partners of childbearing potential: a safe method of
             contraception is practiced during their study participation

          -  Written consent to participate in the study

        Inclusion criteria for randomisation:

          -  At least 6 focal or clonicotonic seizures documented completely in a seizure diary or
             the patient chart during the 8 prospective or retrospective weeks baseline phase.

        Exclusion criteria at screening:

          -  Epileptic state during the past year

          -  Non-epileptic fits

          -  Generalized epilepsy

          -  More than 4 weeks of seizure freedom during baseline phase

          -  Concomitant progressive CNS disease including progressive myoclonus epilepsy

          -  Concomitant treatment with vigabatrine and / or topiramate

          -  Hepatic and/or renal insufficiency (creatine &gt; 2mg% or GPT &gt; 2 times ULN)

          -  Body weight â‰¤ 40 kg

          -  (History of) kidney stones; erythrocyturia, family history (in parents, children,
             brothers and sisters or grandparents) of kidney stones

          -  (History of) drug and/or alcohol dependence

          -  Active psychosis

          -  Suicide attempt during the past 3 years

          -  Pre-treatment with zonisamide

          -  Known hypersensitivity to sulfonamides

          -  concomitant treatment with neuroleptic drugs

          -  pregnant or breast feeding woman

          -  participation in another therapy study within 3 months prior to or during this study

          -  blood donation planned during or within 4 weeks after the participation in this study

          -  elective surgery planned during the participation in this study

          -  patient is not willing or not capable to meet the study demands

          -  patient does not agree to the forwarding of his/her pseudonymous data

          -  patient without legal competence

        Exclusion criteria for randomisation:

        - More than 4 consecutive weeks of freedom from seizure during baseline phase
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Elger</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitatsklinikum Bonn, Klinik fur Epileptologie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Epilepsieklinik Tabor</name>
      <address>
        <city>Bernau</city>
        <state>Brandenburg</state>
        <zip>16321</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universtitatsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <state>Nordrhein-Westphalen</state>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universtitatsklinikum Munster, Klinik und Poliklinik fur Neurologie</name>
      <address>
        <city>Munster</city>
        <state>Nordrhein-Westphalen</state>
        <zip>48129</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Epilepsiezentrum Bethel/KSE</name>
      <address>
        <city>Beilefeld</city>
        <zip>33617</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut fur Diagnostik der Epilepsien Gmbh</name>
      <address>
        <city>Berlin</city>
        <zip>10362</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Campus Virchow-Klinikum, Neurologische Klinik und Poliklinik</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Josephs Hospital, Neurologische Klinik</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Gunther Schumann</name>
      <address>
        <city>Bochum</city>
        <zip>44805</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Knappschaftskrankenhaus Bochum-Langendreer, Neurologische Klinik</name>
      <address>
        <city>Bochum</city>
        <zip>44892</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Hans Martin Kolbinger</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuro-Consil Gmbh</name>
      <address>
        <city>Dusseldorf</city>
        <zip>40212</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologische Klinik der Universitat Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinik Essen, Klinik und Poliklinik fur Neurologie</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Freiburg, Neurozentrum</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Gottingen, Abt. fur klinische Neurophysiologie</name>
      <address>
        <city>Gottingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftpraxis fur Neurologie und Psychiatrie</name>
      <address>
        <city>Hamburg</city>
        <zip>22083</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Heinrich C. Braeuer</name>
      <address>
        <city>Hamburg</city>
        <zip>22299</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ev. Krankenhaus Alsterdorf, Epilepsiezentrum Alsterdorf</name>
      <address>
        <city>Hamburg</city>
        <zip>22337</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Epilepsiezentrum Kork</name>
      <address>
        <city>Kehl</city>
        <zip>77694</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Epilepsiezentrum Kleinwachau, Epilepsieambulanz</name>
      <address>
        <city>Liegau-Augustusbad</city>
        <zip>01465</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Mannheim, Neurologische Klinik, Ambulanz fur Anfallserkrankte</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum, Interdisziplinares Epilepsiezentrum</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Grosshadern, Neurologische Klinik und Poliklinik, Epilepsie-Ambulanz</name>
      <address>
        <city>Munchen</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Offenbach, Neurologie</name>
      <address>
        <city>Offenbach</city>
        <zip>63069</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik Ernst von Bergmann</name>
      <address>
        <city>Potsdam</city>
        <zip>14467</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitat Regensburg, Klinik un Poliklinik fur Neurologie</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik &quot;Die Weissenau&quot;, Anfallsambulanz</name>
      <address>
        <city>Revensburg</city>
        <zip>88214</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitat Rostock, Klinik fur Neurologie und Poliklinik</name>
      <address>
        <city>Rostock</city>
        <zip>18147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinik Ulm Poliklinik fur Neurologie, Epilepsieambulanz</name>
      <address>
        <city>Ulm</city>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Horst-Schmidt Klinik, Neurologie</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2005</study_first_posted>
  <last_update_submitted>June 26, 2014</last_update_submitted>
  <last_update_submitted_qc>June 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epilepsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Seizures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zonisamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

